Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Subjects

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Sanofi ( Sanofi Pasteur, a Sanofi Company )
ClinicalTrials.gov Identifier:
NCT00875524
First received: April 2, 2009
Last updated: January 24, 2014
Last verified: January 2014

April 2, 2009
January 24, 2014
March 2009
August 2014   (final data collection date for primary outcome measure)
  • Immunogenicity: To provide information concerning the immune response to ChimeriVax™ tetravalent dengue vaccine [ Time Frame: 28 days post-vaccination ] [ Designated as safety issue: No ]
  • Safety: To provide information concerning the safety of ChimeriVax™ tetravalent dengue vaccine [ Time Frame: 28 days post-vaccination and entire study duration ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT00875524 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Subjects
Immunogenicity and Safety of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Subjects Aged 2 to 45 Years in Viet Nam

This trial will evaluate the use of a tetravalent vaccine against dengue.

Primary objectives:

  • To describe the immune response to dengue before and after each vaccination with tetravalent dengue vaccine in adults, adolescents, and children.
  • To evaluate the safety of each vaccination with sanofi pasteur's tetravalent dengue vaccine in 4 age cohorts.
  • To evaluate the persistence of antibodies against dengue during 5 years after the first vaccination with sanofi pasteur's tetravalent dengue vaccine in the four age cohorts.
Not Provided
Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Single Blind (Outcomes Assessor)
Primary Purpose: Prevention
  • Dengue Virus
  • Dengue Fever
  • Dengue Hemorrhagic Fever
  • Dengue Disease
  • Biological: Chimeric dengue serotypes (1, 2, 3, 4).
    0.5 mL, Subcutaneous
    Other Name: ChimeriVax™
  • Biological: Meningococcal Polysaccharide A+C; NaCl; Typhoid Vi polysaccharide
    Each at 0.5 mL, Subcutaneous, respectively
    Other Names:
    • Meningococcal Polysaccharide Vaccine A+C
    • NaCl
    • Typhim Vi®
  • Experimental: Dengue Group
    Participants will receive ChimeriVax™ tetravalent dengue vaccine.
    Intervention: Biological: Chimeric dengue serotypes (1, 2, 3, 4).
  • Sham Comparator: Control Group
    Participants will receive Meningococcal Polysaccharide Vaccine A + C, a placebo (NaCl containing human serum albumin), and Typhoid Vi polysaccharide vaccine (Typhim Vi®) as first, second, and third vaccinations, respectively.
    Intervention: Biological: Meningococcal Polysaccharide A+C; NaCl; Typhoid Vi polysaccharide
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
180
December 2014
August 2014   (final data collection date for primary outcome measure)

Inclusion Criteria :

  • Aged 2 to 45 years on the day of inclusion.
  • Provision of Informed Consent/Assent Form signed by the subject (and/or by the parent or another legally acceptable representative for subjects <18 years).
  • Subject (and parent/guardian for subjects <18 years) able to attend all scheduled visits and to comply with all trial procedures.
  • For a female subject of child-bearing potential, avoid becoming pregnant (use of an effective method of contraception or abstinence) for at least 4 weeks prior to the first vaccination, until at least 4 weeks after the last vaccination.
  • Subject in good health, based on medical history, physical examination and laboratory parameters.

Exclusion Criteria :

  • Personal or family history of thymic pathology (thymoma), thymectomy, or myasthenia.
  • For a female subject of child-bearing potential, known pregnancy or positive serum pregnancy test at Screening.
  • For a female subject of child-bearing potential, known pregnancy or positive urine pregnancy test on the day of the first injection.
  • Breast-feeding female subject.
  • Receipt of any vaccine in the 4 weeks preceding the first trial vaccination.
  • Human immunodeficiency virus, hepatitis B, or hepatitis C seropositivity in the blood sample taken at screening.
  • Planned participation in another clinical trial during the first year of the study.
  • Known or suspected congenital or acquired immunodeficiency, immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the past 6 months, or long-term systemic corticosteroids therapy.
  • Known systemic hypersensitivity to any of the vaccine components or history of a life-threatening reaction to the trial vaccines or to a vaccine containing any of the same substances.
  • Chronic illness at a stage that could interfere with trial conduct or completion, in the opinion of the Investigator.
  • Current alcohol abuse or drug addiction that may interfere with the subject's ability to comply with trial procedures.
  • Receipt of blood or blood-derived products in the past 3 months that might interfere with the assessment of immune response.
  • Subject deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized without his/her consent.
  • Laboratory abnormalities of at least moderate severity or clinically significant according to the Investigator in blood sample taken at screening.
  • Participation in another clinical trial investigating a vaccine, drug, medical device, or a medical procedure in the 4 weeks preceding the first trial vaccination.
  • Planned receipt of any vaccine in the 4 weeks following the first trial vaccination.
  • Familial atopy medical history (parents, brothers, or sisters).
  • Previous vaccination with meningococcal A+C or typhoid vaccines within 3 years prior to inclusion.
  • History of meningococcal or typhoid infections (confirmed either clinically, serologically or microbiologically).
Both
2 Years to 45 Years
Yes
Contact information is only displayed when the study is recruiting subjects
Vietnam
 
NCT00875524
CYD22
No
Sanofi ( Sanofi Pasteur, a Sanofi Company )
Sanofi Pasteur, a Sanofi Company
Not Provided
Study Director: Medical Monitor Sanofi Pasteur Inc
Sanofi
January 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP